French Pharma major Sanofi is planning to launch multiple best-selling drugs from its global pipeline in India. According to media reports, the company is planning to revamp its strategy in India.
According to a report by Mint, Sanofi is “ambitious” about widening its presence in India and the company claims it is still a “under-represented market”. Reportedly, the pharma major has a lot of plans to “double down” in India.
As part of its strategy, the company will introduce some new products, including its pre-mix insulin drug Soliqua, and Xenpozyme, which is used to treat late-onset Pompe disease, Mint reported.
According to a company statement, other new drugs in the pipeline include Dupixent, indicated for eczema in adults, respiratory-virus drug Beyfortus and Mexiviazyme.
Reportedly, this strategy may also increase access to Sanofi’s existing product portfolio in India which includes Lantus, Clexane, Targocid, Allegra, Enterogermina, Combiflam Cardace and Cerezyme, etc.
The company is also looking at widening access through partnerships with companies like Cipla, Dr Reddy’s Laboratories, and Emcure.
Last week, the company announced a partnership with Dr Reddy’s to promote and distribute paediatric and adult vaccine brands such as Hexaxim, Pentaxim, and Tetraxim.
Similarly, Sanofi will distribute its Central Nervous System (CNS) product range in India. This includes six brands, including Frisium anti-epileptic drugs through its partnership with Cipla.
